(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 November 2020 (05.11.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/223541 A1

(51) International Patent Classification:
A61K 38/17 (2006.01) *A61P 11/06* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2020/030824

(22) International Filing Date:
30 April 2020 (30.04.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/841,481	01 May 2019 (01.05.2019)	US
62/848,248	15 May 2019 (15.05.2019)	US
62/898,900	11 September 2019 (11.09.2019)	US

(71) Applicants: **SANOFI BIOTECHNOLOGY** [FR/FR]; 54, rue La Boétie, 75008 Paris (FR). **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors; and

(71) Applicants: **GOULAOUIC, Helene** [US/US]; c/o Sanofi, 55 Corporate Drive, Mail-Code 55A-505A, Bridgewater, New Jersey 08807 (US). **JESSEL, Andreas** [US/US]; c/o Sanofi, 55 Corporate Drive, Mail-Code 55A-505A, Bridgewater, New Jersey 08807 (US). **ABDULAI, Raolat** [US/US]; c/o Sanofi, 55 Corporate Drive, Mail-Code 55A-505A, Bridgewater, New Jersey 08807 (US). **TEPER, Ariel** [US/US]; c/o Sanofi, 55 Corporate Drive, Mail-Code 55A-505A, Bridgewater, New Jersey 08807 (US).

(72) Inventors: **RUDDY, Marcella**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **AMIN, Nikhil**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **HAREL, Sivan**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SZAFRAN, Weronika**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **HUBER, John**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw

(54) **Title:** METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-33 ANTAGONIST




Fig. 1

(57) **Abstract:** The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-33 (IL-33) antagonist, such as an anti-IL-33 antibody. The methods featured in the invention further comprise administering to a subject in need thereof a first therapeutic composition comprising an interleukin-33 (IL-33) antagonist, such as an anti-IL-33 antibody, and a second therapeutic composition comprising an interleukin-4 receptor (IL- 4R) antagonist, such as an anti-IL-4R antibody.

WO 2020/223541 A1

[Continued on next page]

Mill River Road, Tarrytown, New York 10591 (US). **POLS, Joanna**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) **Agent: VELEMA, James H.**; Lathrop GPM LLP, 28 State Street, Boston, Massachusetts 02109 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*